The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium)

European Journal of Pediatrics

Volumn 161, Issue 11, 2002, Pages 588-593

  Thiry, Nancy ^a   Beutels, Philippe ^a   Shkedy, Ziv ^b   Vranckx, Robert ^c   Vandermeulen, Corinne ^d   Van Der Wielen, Marie ^a   Van Damme, Pierre ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adolescents; Clinical history; Seroprevalence survey; Varicella zoster virus

Indexed keywords

ACCURACY; ADOLESCENT; ADULT; AGE; ARTICLE; BELGIUM; BLOOD ANALYSIS; CHICKENPOX; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FAMILY; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RELIABILITY; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BELGIUM; CHICKENPOX; CHILD; CHILD, PRESCHOOL; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; MENTAL RECALL; SEROEPIDEMIOLOGIC STUDIES;

EID: 0036460082     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-002-1053-2     Document Type: Article

References (41)

1. Aebi C, Fischer K, Gorgievski, M Matter L, Mühlemann K (2001) Age-specific seroprevalence to varicella-zoster virus: Study in Swiss children and analysis of European data. Vaccine 19: 3097-3103
2. Algemene Vereniging van de Geneesmiddelenindustrie (2001) Compendium, 19th Edn. Claessens, Brussels
3. Beutels P, Van Damme P, Van Doorslaer E (2000) Program Evaluation of Universal Varicella Vaccination in Belgium. ESOC publication Nr 36, University of Antwerp, Belgium
4. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, Coplan P, Sharrar R, Guess H (1999) Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 18: 1041-1046
5. Boulianne N, Duval B, De Serres G, Deceuninck G, Massé R, Couillard M (2001) Most ten-year-old children with negative or unknown histories of chickenpox are immune. Pediatr Infect Dis J 20: 1087-1088
6. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G (2001) Epidemiology of varicella zoster virus in Canada and the United Kingdom. Epidemiol Infect 127: 305-314
7. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ (2002) Exposure to varicella boosts immunity to herpes-zoster: Implications for mass vaccination against chickenpox. Vaccine 20: 2500-2507
8. Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E (1986) Risk of herpes zoster in children with leukemia: Varicella vaccine compared with history of chickenpox. Pediatrics 77: 53-56
9. Choo PW, Donahue JG, Manson, JE Platt R (1995) The epidemiology of varicella and its complications. J Infect Dis 172: 706-712
10. Committee on Infectious Disease (1995) Recommendations for the use of live attenuated varicella vaccine. Pediatrics 95: 791-796
11. Fairley CK, Miller E (1996) Varicella-zoster virus epidemiology - A changing scene? J Infect Dis 174[Suppl 3]: S314-S319
12. Gabutti G, Penna, C Rossi M, Salmaso S, Rota M, Bella A, Crovari P (2001) The seroepidemiology of varicella in Italy. Epidemiol Infect 126: 433-440
13. Garnett GP, Grenfell BT(1992) The epidemiology of varicella-zoster virus infections: The influence of varicella on the prevalence of herpes zoster. Epidemiol Infect 108: 513-528
14. Gershon AA, Takahashi M, White CJ (1999) Varicella vaccine. In: Plotkin SA, Orenstein WA (eds) Vaccines, 3rd Edn. Saunders, Philadelphia, pp 475-507
15. Gershon AA (2001) Live-attenuated varicella vaccine. Infect Dis Clin North Am 15: 65-81
16. Gray GC, Palinkas LA, Kelley PW (1990) Increasing incidence of varicella hospitalisations in the United States army and navy personnel: Are today's teenagers becoming more susceptible? Should recruits be vaccinated? Pediatrics 86: 867-873
17. Guess HA, Broughton DD, Melton LJ, Kurland LT (1986) Population based studies of varicella complications. Pediatrics 78: 723-727
18. Halloran E (1996) Epidemiologic effects of varicella vaccination. Infect Dis Clin North Am 10: 631-655
19. Hardy I, Gershon AA, Steinberg SP, LaRussa P (1991) The incidence of zoster after immunisation with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med 325: 1545-1550
20. Harel Z, Ipp L, Riggs S, Vaz R, Flanagan P (2001) Serotesting versus presumptive varicella vaccination of adolescents with a negative or uncertain history of chickenpox. J Adolesc Health 28: 26-29
21. Heininger U, Braun-Fahrländer C, Desgrandchamps D, Glaus J, Grize L, Wutzler P, Schaad UB (2001) Seroprevalence of varicella-zoster virus immunoglobulin G antibodies in Swiss adolescents and risk factor analysis for seronegativity. Pediatr Infect Dis J 20: 775-778
22. Izurieta HS, Strebel PM, Blake PA (1997) Post-licensure effectiveness of varicella vaccine during an outbreak in a child care centre. JAMA 278: 1495-1499
23. Jaeggi A, Zurbruegg RP, Aebi C (1998) Complications of varicella in a defined central European population. Arch Dis Child 79: 472-477
24. Kanra G, Tezcan S, Badur S (2002) Varicella seroprevalence in a random sample of the Turkish population. Vaccine 20: 1425-1428
25. Kind en Gezin (2000) Het kind in Vlaanderen, 2nd edn. Van-denberghe, Brussels
26. Lieu TA, Black SB, Takahashi H, Ray P, Capra AM, Shinefield HR, Adler NA (1998) Varicella serology among school age children with a negative or uncertain history of chickenpox. Pediatr Infect Dis J 17: 120-125
27. Miller E, Marshall, R, Vurdien J (1993) Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol 4: 222-230
28. Miller E, Vurdien J, Farrington P (1993) Shift in age in chickenpox. Lancet 341: 308-309
29. OECD (2001) Education at a Glance - OECD Indicators. (http://www.oecd.org)
30. Pastuszak AL, Levy M Schick B (1994) Outcome of maternal varicella infection in the first 20 weeks of gestation. N Engl J Med 330: 901-905
31. Preblud SR (1986) Varicella: Complications and costs. Pediatrics 78: 728-735
32. Ronan K, Wallace MR (2001) The utility of serologic testing for varicella in an adolescent population. Vaccine 19: 4700-4702
33. Salleras L, Domínguez A, Vidal J, Plans P, Salleras M, Taberner JL (2001) Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 19: 183-188
34. Skull SA, Wang EEL (2001) Varicella vaccination - A critical review of the evidence. Arch Dis Child 85: 83-90
35. Thiry N, Beutels P, Van Damme P, Van Doorslaer E (2002) Economic evaluations of varicella vaccination programmes: A review of the literature. Pharmaco-economics (in press)
36. Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED (2001) The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344: 955-960
37. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB, Scolnick EM (1984) Live attenuated varicella virus vaccine. Efficacy trials in healthy children. N Engl J Med 310: 1409-1415
38. Wharton M (1996) The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 10: 571-581
39. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, Krause PK (2000) Post-licensure safety surveillance for varicella vaccine. JAMA 284: 1271-1279
40. Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2002) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20: 121-124
41. Yawn B, Yawn R, Lydick E (1997) Community impact of childhood varicella infections. J Pediatr 130: 759-765